Dovato is indicated for the treatment of HIV-1 in adults and adolescents above 12 years weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. 3
- European AIDS Clinical Society Guidelines Version 10.0. November 2019. https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf. Accessed April 2020.
- Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed April 2020.
- DOVATO Summary of Product Characteristics. https://www.medicines.ie/medicines/dovato-50-mg-300-mg-film-coated-tablets-34871/smpc. Last accessed: June 2020.